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• L n e r  Angloplasty for Within Stent Restenosls - 
Final Results of the LARS 5urvelllsnce Study 
C,W Harem, R Simon, R,J Seabra Gomea, H, Sloven, C, Macaya, 
E, Fleck, J J  Bonn or, R, K0sler, PW. Serruys. The LARS Sfuc/y 
tnv¢$fl~lOt~: U n ~ t ~ t y  Hospital ERpendo#, H#m~r~, Germ~rry 
Corof~ry ~Imlting is asso¢tat~ with a msleno~ts rotes of 10 to 20%. When 
treated with re~aat PTCA th~ m c g f f e ~  rate ~ n  be as high as 80%. The 
l e f ~  restdt may b~ mo~ f~vo~l'a~ by 0g~cu!king tissue like with oximer 
I~set com~aw engiol~sly (ELA), 
Met/'m~: In It.s ~ i t v e ,  mgit~enler sludy we investigated ~ffety and 
e f f ~ " Y  O! ELA With a d j ~  FTCA in ~ t i ~  (~.70% diaft~_ter stesoeis) 
or o c g ~  slenls in 4!4 v e ~  (88% n~lW~. ! ~ .  ~ i n  grafts) w~th 494 
steels implanted, The k~sion length was 19,0 ± 13,1 ram with ~_ ~ffomnt 
tyl~. ~s o! ~lents (25% AVI~. !9% Palmaz.Schatz) implanted 5,8 months puor 
~ -  ~ten0sls diameter was ~ by El-A, to 42 ± 16% and after 
a ~ u ~  PTCA (12.6 ± 4,0 aim) to 7 ± 12%, P ~ I  success, was 
~ in g~=, C o l l l p l i c a ~  aft(IF EL~ were rag*stared in 5? pa.tmnta 
(13.8%) iac.lu~ing 2 r~nor p a r ~ 0 r a ~  and 20 d i s s e c t ~  (48%). Afte~ a ~  
iunctt~ FTCA in 411 ~ Ihere ware 2 more perforations and 45 more 
diSSeCl~nS (10 9%) which re~t~re~ a d d i ~ l  steals in 67 pts (16%). Steal 
d a ~  (n ; 2) and pencafdml tamponade (n : 2) were rare Dunng hospP 
talt~ation !here were 6 deaths (n = 3 cerebral hemonhages), 2 myocarOal 
i n f a ~  and t0 non4~wave infarctmns. 
C o ~ . :  ELA was safe and effectnm in treatment oF restenoses wrlhin 
stents Long term results are pending 
~ R m t  Clink:at I ~ ~  W i t h  ~ ¢ u l a r  L o w  
PcmN~r r a d  I L a ~  L i g h t  1RIteralw f o r  IRrevention o f  
~ i s  Following COrOnary S t e a l i n g  
I. De ,Scheerder, K. Wang, M H  Keelan, Jc N Kq~shidze. Univetsa~y 
~ s  L eu~n. Belgium 
Backg~,-ound: Low power red laser light therapy (LPRLT) has been shown to 
reduce msteno~s follo~r, ng balk:~on a n g i o p ~  in animal models. 
Methods: The purpose o! this study was to determine the safety and 
efficacy of LPRLT to pmvant restenosis fol~-~m~ coronary sten~ng. Three 
groups o! patmnts received LPRLT using the coPJ t--et illuminator" (Global 
Therapeutics. Boulder, CO) w ~  a laser p'c'.:..'~ cf ~ t J/cm ~. Group I 
II included patients w~th erlher a sut~3pbmai ang~plasty result (n = 26), or 
~ r r e n t  restenos=s after balloon angtuptasty (n = 24). Group III included 20 
patients wdh restenosis following coronary steflting 
Results: The primary success rate was f00%. No maior in-h~spdal com- 
plK:abons occurred dunng this study Thirteen pahents underwent a control 
ang~ogram because el recurrence of an~na pectons A s~gnificant steal 
stenosls was found in only 5 patients Elective coronamgram at 6 months 
was perfon'ned in another 49 pts. Restenos~s (DS ~ 50¢°) was found in 9 pts 
O8.4%). Quanbtatwe coronary analysis per les~on treated: mimmal furmnal 
diameter (MLD) pre: 0.8 ~ 0.5 ram, pest: 2.9 • 0.6 ram. follow.up: 1.9 ± 0.6 
mm. Restenosts rate was 20.6% 
Conctuston: These preliminary results suggest that LPRLT after coronary 
stenting ts feasible and safe and potentially has a benefioal effect on steal 
restenosis in this high risk patient population. A multicenter randomized htal 
to confirm these results is pending. 
R e s t e n o s i s :  N e w  I n s i g h t s  
M o n d a y ,  M a r c h  3 0 ,  1 9 9 8 ,  3 : 0 0  p . m . - 5 : 0 0  p.m. 
G e o r g i a  W o r l d  C o n g r e s s  C e n t e r ,  W e s t  E x h i b i t  Hall L e v e l  
P r e s e n t a t i o n  H o u r :  3 : 0 0  p . m . - 4 : 0 0  p . m .  
~' -8 - ]  Neointimal and Not Adventiflal Plays Proliferation 
a Role in Restenosis After Percutaneous 
Transluminat Coronary Angioplasty in Humans - 
A H i s t o m o r p h o m e t r i c  A n a l y s i s  
R. Komatsu. M Ueda, T. Naruko, A. Koiima, A.E. Backer. Osaka City 
Umversity Medical School, Osaka, Japan; Academic Medical Center. 
Amsterdam, The Netherlands 
Background: Late vascular recoil, considered to result from edventitial prolif- 
eration, rather than neointimal formation is presently promoted as the cause 
of restenosis (RS) after percutaneous transfuminal coronan/ angioplasty 
(PTCA) in humans. 
Material and Methods: Of an autopsy senes of 92 post-PTCA patients and 
based on follow-up angiographic cdleria, we performed histomorphometdc 
surface area analysis of 18 coronary arteries with RS (;n;~,~al PTCPJdaalh 
= 2 mos ~ 2 yrs) and of 5 coronary arteries with luminal narrowing but 
not meeting the cnlefia of RS (inlewai PTCA/doath = B rues 2 yrsl The 
proximal non~lilated sites flowed as reference 
Result,, All PTCA sites showed ~ n t i m a l  tisstm, albe=l to varying de. 
ureas The moan luminal area at PTCA silos was e=pressea aS a ratio C ,t 
rn# mean luminal area af m t o m ~ o  sites. This rat~ W~s ~lnificsnfly (p .: 
0,0001) 10w~r at RS sites (0246 _+ 0,104) ttmn st non-RS s~tes (0.692 
0.~40), Area quantification of ~ adverffiti~ showe~ tlo statisli(~tlly s~f~..ant 
~ffomn¢~ t~lwesn RS a ~  non-RS I~K~IlS, The t n ~ n  neomliml area was 
@ s p f ~  as # i~liO of 111~ mean lq~l~L~nlife,~l ~re~ ,~ Iumir~! aea~. Th~s fsfio 
W~S significantly (p ~: 0,01 ) I~gher al flS sites (9,779 ± 0, t 08) than at no~- fl$ 
sites (0545 ~ 0,0~.1) The ~ total v ~ e l  ~rea was s~lnif~mtly (p < ~,01 ) 
~ r  at RS ~!tas (10916 ¢ 2,849 mm ~) fhah at reference sites (92.50 
;2,072 mm ~) 
Conctuag~na: These obse~/atto~s COetradict ~ k w  role tar adventttiat 
pfolifor~t~ as a cause of resteno~ls after PTCA in humans, but father 
emphasizes the rote of the neoin~ma 
• Plasma UmkintN  Antigen Levels Predict 
A n g m g r a p h i e  R e s l e f l o i I l  
BH. Strauss. I Smgh, H.K. Lau, K.A. Bowman, J M  Teitel. J,O Sparkes, 
M B  Gawery, M K  Nataraian, R.J Chisholm St M:chae£s Hospital, 
Tomma Canaaa 
Purpose: TO determine the relationship between restenosis and plasma lev. 
els el umkinase anligen (UK), urokioase ~ (uPA), tissue plasmmogen 
activator (tPA), of plesmmogen activator inhibitor (PAl). 
~ :  In a prosgeclwe study enrolling 159 pal~enle (pts), plasma levels 
of UK. uPA. tPA. PAl were drawn immediately before and serially after eteclwe 
PTCA/stenting of a de nova lesion in a native coronary artery Restenosis, 
defined as >50% resK/ual lumen diameter slenosis by quantitative coronary 
angmgraphy was datem~ned at 6 months. 
Results: To date. 116 of 126 (92%) of elig=ble pls. have had angJographlc 
toltow~up. In the overa, group, uPA levels showed a significant increase 
at and beyond 3 days postprocedure. The resfenos=s rate was 24%, The 
"restenosis" group had higher UK levels overall (including pre-PTCA) than 
the "no restermsm" group (Figure). No s~gniflcant differences were observed 
in the tPA and PAl levels between I1~ two groups. 
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Conclusions." Plasma urekinase antigen levels identify a group el patients 
at nsk for restenosis post-PTCA Plasma urokinase actnnty levels elevate 
significantly 3 days IDOst-PTCA 
I 1062-1001 A t h e r o s c l e r o t i c  P r o g r e s s i o n  in t h e  P r o x i m a l  
' N o n - t r e a t e d  S e g m e n t  in Patients U n d e r g o i n g  
C o r o n a r y  I n t e r v e n t i o n s  Evaluated b y  
I n t r a v a s c u l a r  U l t r a s o u n d  
J. Ge, F bu. G. Gdrge. M Hauda. V. Shah, R ErbeL Dept at Cardlo/og~ 
University Essen. Germany 
B~ckground: Injury of the endothelial cells may result in plaque formallon 
Purpose of the study waS to evaluate the alhemsclemtic changes in the 
proximal non.treated segments in patients who underwent PTCA 
Metheds: Intravascular ultrasound (IVUS) was performed in 59 patients 
(51 males, aged 55 • 9 yre) immediately pest successful PTCA and 6 months 
follow-up using a 3.5 F, 20/30 MHz IVUS catheter (Sonicalh, Boston ScientiI~c 
Co). The vessel and plaque areas in the proximal and distal non-treated 
reference segments 2 em proximal and disfa! to the intervention segment 
were evaluated 
Resu;rs: No significant differences were found concerning the vessel 
areas between initial 9xaminaticr~ at~d at 6-month it!low-up in the proximal 
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and distal non.lrosted sagmenls. Plaque area In the distal segment showed 
also no signklcsnt increase. A signillcnnl increase 01 IhQ plflque area rn the 
pmslmnl sagmont wss found at &month fOllOW*UP. 
- 
Prox~mnl soamonl Dlntnl soomant 
pant PTCA lollow.up pmt PTCA lallowup 
~~seel Rtsn(mm2) 20.1 t 6.7 10.7 L G.Apn 0.52 14.2.1 3.0 13.0 i: 3.7PnO.46 
p1q~ln~ron(mm") 7.3. t.3.7 7.0 C 4.U' pmO.010 6.7 -i 3.4 6.2 zk 3.6 PC 0.10 
c~ncluslan: IVUS domanslrated A plaque progresslon only In the proxlmsl 
nan+asled segmen\ but not In the distal non4realQd sogmant suggashng 
lhst alhQronclarollQ prograflalon ,rilght ba pnnly rosultad ham ondolhallsl 
dsmngaa during Imorvanllon such sn bnlloon pflsRng0. 
New Method8 to lnhlblt Neolntlmal 
Hyperplaela 
Monday, March 30, 1999, 300 p.m.-300 p.m. 
Georgia World Congress Canter, West Exhlblt HRII Level 
Presentation Hour: 3:OO p.m.400 p-m, 
Selsctlve ET& Receptor Antagonlam Raducaa 
Naolntlmal tiyperplaala In a Parclne COrOnarY 
Stent Mods1 
C.J. McKrmnn, SE. Surko' , T.J. Qpganorlh’ , R J. Podlay’, L.D.J. Cnmrud. 
AR. Cnmrud, P.J. Carlaon. A. Lannnn, CR. llalmaa. Jr,, FL.53 Schwartz. 
D/tis(on al CardmvascuBr Diseases, Mayo Cllnlc, Rachesfer. MN. USA: 
r Abbotf Lnbomfarlas. Abbolt PM, IL, USA 
Esckgroud: Endothalln blndlng to ETA allmulnlas vnsculnr smoalh muscle 
cell pmllfamtlon nnd, thus. may be plvolnlly lnvolvod In Iho palhogonasm 
of restQnosls. This study was daslgnad lo flasoss tha nblllty al a patant 
nnd soloctlve ETA onlngonlst to mduca noolnllmnl hyporplflsm In a pamlno 
coronary stem In)ury modal. 
Methods and Rosub: Oml drug wfls admlnlstorad twlca dally In capsule 
torn? Qt dnRQR of a.75 mg&g (low), 3.75 mglkg (mid) and 10.6 mglkg (high). 
Fllty-seven plgs had stents doployed In anch ol two rnndomly asslgnod major 
oplcardlnl coranary mtarlas. Thlnaon plgslgmup survlvod wilhoul compllca 
tlon until predetannmad sncrllice al 28 days. ET.1 lmmunoraectivily was 
observod wlthln tho noolntima of nil stonlod comnnty sogmonls and concan. 
tratod nt lho silos of strut mtury. Compamd to placebo. injuty was stgnlhcnntly 
grenlar in mtd nnd htgh dose gmups. whtlo naotntimel Ihtcknass (NI) was $19 
nWmlly lass m low nnd high doso ~nimnls. 
___ 
Pi.llV!xl 1 Oh #PSP AhI dose __ ._._. -. - - .- _~___~_~ .-___-_ 
IrliUrY scorn 1 73 , 080 179 IO7:, IO4 1 092’ 
NI (mm) 0 45 t 0 24 0 38 t 0 22’ 0.40 * 0.25 -- 
(‘P 005) 
Hrgh dose 
1 !lJ I 0 73’ 
0 37 t 0.37’ 
Coflcfusion: Ornl solaclivo ETA recoplor rtnlngonism stgnilicanlly reduces 
noomtimttl hyporplnstn in Iho first 26 days following coronary stenling in Ihis 
porcine modal and. thus. has clinical potontlnl for limiting coronary rastenosis 
tollowing porcutnnaous revasculortration. 
I-1 1063 102 Tranllast Is More Etfectlve on Restenotlc Leslon 
Than de Nova Lesion for Prevention of 
Restenosls 
S. Matsui. H. Tamai. K. KrUou. H. Hayakawa. T. Yamekawa. K Kanmalsuse. 
K Hare. T. A~zswa. N. Nakamshl. S. Suzuki, T. Suzuki, S Takase. 
H. Nishikawa. T’REAW study invasfigafors: Shiga Medical Center for Adull 
Dseases. Mon~.ema. Japan 
We have al~ady reported the efficacy of trantlast on preventlon of restenosts 
tOllOwIng perCUtaneOuS translumional coronery angtoplasty (PEA) in the 
multicenter study (TREAT-P). In the sludy, we also analized the dtfference 
of the responses on de nova lesions or restenosts lesions following PTCA. 
Trantlast was gtven 600 mg Per day over 6 weeks attor successlul PTCA and 
folloWuP angiograms were performed at three monlhs. Data were analized 
by CCA, snt restenosis was defined as a lass of more than SO% at inittal 
gain. 
lesion 
lranllasl (It) 
plncebo,“, 
rest8”0515 ra,e ,“0, 
donovo restenos,s 
ia9f7.v 17 9 (39) 
41 2(97) 53.3 (30) 
diameter stenosis (%) 
donovo restenosis 
42 I t 20.4 42.3 i 21.5 
45.6 i 18.8 54.7 * 22 3’ 
JACC RhnliIv IWX 
Trsnllast reduced the restenosls rate both for de novo lesions and restenosls 
loslons. However, the reducllon of reslonosls rnto we8 54% In de novo le. 
slons and 66% In roslenotlo leslons compared wllh Iho placebo gmups. In the 
placebo groups, the percent diameter slenosls at follow up period of resteno. 
ala leslon wss slgnlfloantly larger lhsn that of de novo lesion (’ p = O.O2S), also 
lho bolh were slmllsr In tranllasl groups. The results Imply that trsnllss\ was 
more offecllve for preventlon of restenosls followlng re.PTCA agalnst resle. 
nosls. Tho mechanism may depend on the psthologlcal basis of the lesion. 
Tranllart Inhlblta Noolntlms Formation In 
Balloon-Injured and Stonted Pig Coronary 
ARorle8, end Decrea1108 Negative Romodollng 
After Balloon ln]ury 
S. lahlwotn, N.A.P. Chronos, Q. lln, J-J. Mmshsll, S.B. King, 111, 
K,A. Roblnson. De~rfman~ of tWerIc/nQ (CrQrWagy~, Emory Univ?mifY 
School al Madk~m. Atlanta, &IA: VA MedIcal Cenrer, Allonta, (iA, USA 
Fow phannnoologla nganla aftact restanosm cllnically. A recent huge mum= 
cenlar trml (TREAT) shawad benekt (15% restsnosm rata) at the anli-allew 
nnd nnli.kolold oompaund To conlw thus result and ascerlsin the posse. 
bla machnnism wa gsva 100 mgncg hanilast twme/d for 3 d More balloon 
anglaplnsty In the LAD and LCX, and stenhng in the RCA tn 18 pugs and 
conlinuad until hssua hntvosl al 28 d. Contrals (n ‘i la) received angiaplesty 
and slam only. Camnary specimans (stems processed tn situ) were analyzed 
by somaulenrod hlstomorphomaby. 
Resulfs: Trnnilast stgntltaantly drcmasad noatnbmn SIZO (IA) normakrod 
to the orlen~ 01 rnlury (FL) nnd increased lumen size (LA) relskve to ovemtl 
voaasl alxa (VA) in ballwn4nhmrd vassals; advenhha siao (AA) as an index 
of rfrmOdQllng. was decreased. 
lklllooncd WSJ& IPJFL LANA AA 
control 074 ,019 04R i 0.w 052 t 021 
mulnnl 047 t 009 o!at 009 043t014 
1’ va1ua Sludonll 00001 0 0038 00037 
Trnnilnsl nlso tnhibttod neotntlma lormalton whether axpressed as abso- 
Iulo area (slallstical trend) or relalive lo the extent of m(ury (IS). tn stented 
vassels 
IA l&IS 
407 f 042 TaBt 027 
trmlasl 3.26 t 04 204t025 
p valuoSludonll 0136 0022 
Conclususcons: Trantlast IS elfeclive lo mhtbtl neomltma IonnatIon and ad- 
venbtial remodetlng m the ptg coronary model of ballwn reslenosts. and 
mhtbils nootnttma tn slants: 11 may be usolul ckntcelly. Studtes lo further 
dokno tho mechanism aro underway. 
1063-l 04 Single InjectIon Sustained Release Anglopeptin 
for Prevention of Late Clinical Events Following 
Coronary Angloplasty 
H. Emanuelsson. M. Aasa. P. Albertsson. 0. Amtorp. J.-P. Sagger. 
M.L. Foegh. .I. HetkkilB. J.J. Papma. J. Renslrup. K. SaunamBkr. 
P. Thayssen. for the Scandinavian Angiopeptin Sfudy Group: Oberero 
Medical Center Hospital. Cbrem. Sweden 
immediate release angtopeplin has prevtousty been shown to decrease clm- 
tcal events followtng PTCA. The purpose of the present study was to assess 
the eflicacy of angtopepbn prolonged release (PR) on the combtned pnmaty 
endpomls 01 deatn. Ml and revasculanzahon tcitowmg PTCA al one year. 
Methods: 274 patients were enrolled al 7 centers m thts randomized 
double-bknd placebo-controlled study. Study drug (30 mg angiopepbn PR or 
placebo) was given as a single mlramuscular injection the day before the 
scheduled PTCA. As in Ihe prevtous study, a booster dose of 375 rig was 
given 15 minutes prior lo inflation. All procedural angiograms were evaluated 
at the core laboratory. Clinical fallow-up was performed at 6 and 12 months. 
Pnmary endpoints were analyzed in a hierarchical manner. 
Resurrs: Follow-up was completed July 3rd 1997. There were 206 males 
(75%) and 66 females (25%). mean age 61 and 57 year, respectively. The 
incidence of diabetes was 9%. Overall. the drug was well tolerated. At interim 
angiographic analysis. study lesions were located in LAD tn 55%, LCX in 19% 
and RCA in 26%. Lesion lenglh exceeded 10 mm in 37% of the cases. Mean 
reference diameter was 2.9 mm. The overall clinical event rate was 26.796 m 
the successful PTCA population at one year. 
Conclusion: In this study, angiopeptin PR was well tolerated. Final eliicacy 
results wtll be available by October 1997. 
